Eitaro Ishisaka1, Kenichi Usami1, Chikako Kiyotani2, Keita Terashima2, Hideki Ogiwara3. 1. Division of Neurosurgery, National Center for Child Health and Development, Tokyo, Japan. 2. Division of Neuro-Oncology, National Center for Child Health and Development, Tokyo, Japan. 3. Division of Neurosurgery, National Center for Child Health and Development, Tokyo, Japan. hideki_o@d5.dion.ne.jp.
Abstract
PURPOSE: Atypical teratoid rhabdoid tumor (AT/RT) is a rare, clinically highly malignant tumor. The extent of the surgical resection may affect survival. However, it is often difficult to perform gross total resection (GTR) at an initial surgery because of the large tumor size and high vascularity. Neoadjuvant chemotherapy may reduce not only the size but also the vascularity. We report our experience, review the literature, and analyze its effectiveness. METHODS: A retrospective chart review of patients who underwent neoadjuvant chemotherapy and second-look surgery was performed. Demographic data, treatment courses, changes in tumor after the chemotherapy, extent of resection and estimated blood loss (EBL) during the second-look surgery, and outcome of each children were evaluated. RESULTS: There are 4 cases. The average age at diagnosis was 13.3 months (2-30 months). Two to 4 courses of neoadjuvant chemotherapy were performed. MRI after the chemotherapy showed reduction of tumor volume, and tumor vascularity at the second-look surgery decreased in all cases. GTR was achieved in 3 cases, and NTR in 1 case. The mean EBL/estimated blood volume (EBL/EBV) was 21.3% (1.5-39%). The mean follow-up period was 23 months (2-48 months). At the last follow-up, 2 patients were alive without recurrence of the tumor (the follow-up periods were 48 and 16 months). CONCLUSIONS: Neoadjuvant chemotherapy for AT/RTs might reduce both tumor size and vascularity, which enabled the maximal tumor resection. It may contribute to improve the prognosis of AT/RT through facilitating the tumor resection.
PURPOSE: Atypical teratoid rhabdoid tumor (AT/RT) is a rare, clinically highly malignant tumor. The extent of the surgical resection may affect survival. However, it is often difficult to perform gross total resection (GTR) at an initial surgery because of the large tumor size and high vascularity. Neoadjuvant chemotherapy may reduce not only the size but also the vascularity. We report our experience, review the literature, and analyze its effectiveness. METHODS: A retrospective chart review of patients who underwent neoadjuvant chemotherapy and second-look surgery was performed. Demographic data, treatment courses, changes in tumor after the chemotherapy, extent of resection and estimated blood loss (EBL) during the second-look surgery, and outcome of each children were evaluated. RESULTS: There are 4 cases. The average age at diagnosis was 13.3 months (2-30 months). Two to 4 courses of neoadjuvant chemotherapy were performed. MRI after the chemotherapy showed reduction of tumor volume, and tumor vascularity at the second-look surgery decreased in all cases. GTR was achieved in 3 cases, and NTR in 1 case. The mean EBL/estimated blood volume (EBL/EBV) was 21.3% (1.5-39%). The mean follow-up period was 23 months (2-48 months). At the last follow-up, 2 patients were alive without recurrence of the tumor (the follow-up periods were 48 and 16 months). CONCLUSIONS: Neoadjuvant chemotherapy for AT/RTs might reduce both tumor size and vascularity, which enabled the maximal tumor resection. It may contribute to improve the prognosis of AT/RT through facilitating the tumor resection.
Entities:
Keywords:
Atypical teratoid rhabdoid tumors; Neoadjuvant chemotherapy; Second-look surgery
Authors: Christian Schneider; Ian Kamaly-Asl; Vijay Ramaswamy; Lucie Lafay-Cousin; Abhaya V Kulkarni; James T Rutka; Marc Remke; Daniel Coluccia; Uri Tabori; Cynthia Hawkins; Eric Bouffet; Michael D Taylor Journal: J Neurosurg Pediatr Date: 2015-05-01 Impact factor: 2.375
Authors: Mark Van Poppel; Paul Klimo; Mariko Dewire; Robert A Sanford; Frederick Boop; Alberto Broniscer; Karen Wright; Amar J Gajjar Journal: J Neurosurg Pediatr Date: 2011-09 Impact factor: 2.375
Authors: Rishi S Kotecha; Katy Burley; Reimar C Junckerstorff; Sharon Lee; Marianne B Phillips; Catherine H Cole; Nicholas G Gottardo Journal: Pediatr Hematol Oncol Date: 2012-07-20 Impact factor: 1.969
Authors: M Benesch; K Bartelheim; G Fleischhack; B Gruhn; P G Schlegel; O Witt; K D Stachel; H Hauch; C Urban; F Quehenberger; M Massimino; T Pietsch; M Hasselblatt; F Giangaspero; U Kordes; R Schneppenheim; P Hauser; T Klingebiel; M C Frühwald Journal: Bone Marrow Transplant Date: 2014-01-13 Impact factor: 5.483
Authors: Meena Thatikunta; Ian Mutchnick; Jennifer Elster; Matthew P Thompson; Michael A Huang; Aaron C Spalding; Thomas Moriarty Journal: J Neurosurg Pediatr Date: 2017-03-10 Impact factor: 2.375
Authors: Roger J Packer; Jaclyn A Biegel; Susan Blaney; Jonathan Finlay; J Russell Geyer; Richard Heideman; Joanne Hilden; Anna J Janss; Larry Kun; Gilbert Vezina; Lucy B Rorke; Malcolm Smith Journal: J Pediatr Hematol Oncol Date: 2002 Jun-Jul Impact factor: 1.289
Authors: D Schrey; F Carceller Lechón; G Malietzis; L Moreno; C Dufour; S Chi; L Lafay-Cousin; K von Hoff; T Athanasiou; L V Marshall; S Zacharoulis Journal: J Neurooncol Date: 2015-11-25 Impact factor: 4.130
Authors: Susan N Chi; Mary Ann Zimmerman; Xiaopan Yao; Kenneth J Cohen; Peter Burger; Jaclyn A Biegel; Lucy B Rorke-Adams; Michael J Fisher; Anna Janss; Claire Mazewski; Stewart Goldman; Peter E Manley; Daniel C Bowers; Anne Bendel; Joshua Rubin; Christopher D Turner; Karen J Marcus; Liliana Goumnerova; Nicole J Ullrich; Mark W Kieran Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544